Alnylam Pharmaceuticals, Inc. $ALNY Shares Bought by Forum Financial Management LP

Forum Financial Management LP lifted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 9.0% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 1,556 shares of the biopharmaceutical company’s stock after acquiring an additional 129 shares during the period. Forum Financial Management LP’s holdings in Alnylam Pharmaceuticals were worth $507,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in the stock. Ethic Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 6.5% in the 2nd quarter. Ethic Inc. now owns 2,176 shares of the biopharmaceutical company’s stock worth $703,000 after acquiring an additional 133 shares during the period. Cullen Frost Bankers Inc. lifted its stake in shares of Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. Cullen Frost Bankers Inc. now owns 10,795 shares of the biopharmaceutical company’s stock worth $3,520,000 after acquiring an additional 78 shares during the period. Mutual of America Capital Management LLC lifted its stake in shares of Alnylam Pharmaceuticals by 16.9% in the 2nd quarter. Mutual of America Capital Management LLC now owns 15,946 shares of the biopharmaceutical company’s stock worth $5,200,000 after acquiring an additional 2,302 shares during the period. Nordea Investment Management AB lifted its stake in shares of Alnylam Pharmaceuticals by 10.4% in the 2nd quarter. Nordea Investment Management AB now owns 11,295 shares of the biopharmaceutical company’s stock worth $3,640,000 after acquiring an additional 1,060 shares during the period. Finally, Sagespring Wealth Partners LLC acquired a new stake in shares of Alnylam Pharmaceuticals in the 2nd quarter worth approximately $299,000. 92.97% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Alnylam Pharmaceuticals

In other news, EVP Jeffrey V. Poulton sold 3,821 shares of the business’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $452.05, for a total transaction of $1,727,283.05. Following the sale, the executive vice president owned 54,052 shares in the company, valued at $24,434,206.60. The trade was a 6.60% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Pushkal Garg sold 3,022 shares of the business’s stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $451.48, for a total transaction of $1,364,372.56. Following the sale, the executive vice president owned 20,221 shares in the company, valued at $9,129,377.08. This represents a 13.00% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 98,144 shares of company stock valued at $44,160,261 over the last three months. 1.50% of the stock is owned by insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on the stock. Canaccord Genuity Group upped their price target on shares of Alnylam Pharmaceuticals from $390.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, August 1st. Oppenheimer raised shares of Alnylam Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $490.00 price target for the company in a research note on Monday, August 4th. Stifel Nicolaus boosted their target price on shares of Alnylam Pharmaceuticals from $441.00 to $495.00 and gave the stock a “buy” rating in a report on Monday, October 6th. Raymond James Financial initiated coverage on shares of Alnylam Pharmaceuticals in a report on Wednesday, July 30th. They issued an “outperform” rating and a $370.00 target price on the stock. Finally, Truist Financial boosted their target price on shares of Alnylam Pharmaceuticals from $459.00 to $535.00 and gave the stock a “buy” rating in a report on Friday, October 17th. Twenty-three research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $466.92.

Alnylam Pharmaceuticals Stock Down 0.1%

ALNY stock opened at $463.43 on Friday. Alnylam Pharmaceuticals, Inc. has a 52-week low of $205.87 and a 52-week high of $495.55. The company’s 50 day simple moving average is $459.27 and its 200-day simple moving average is $360.03. The company has a debt-to-equity ratio of 4.10, a current ratio of 2.80 and a quick ratio of 2.75. The firm has a market capitalization of $60.75 billion, a P/E ratio of -187.62 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, July 31st. The biopharmaceutical company reported $0.32 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.54) by $0.86. Alnylam Pharmaceuticals had a negative net margin of 12.96% and a negative return on equity of 273.52%. The business had revenue of $773.69 million for the quarter, compared to analyst estimates of $633.54 million. During the same quarter in the previous year, the business earned ($0.13) earnings per share. The firm’s revenue was up 17.3% compared to the same quarter last year. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, equities research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.